Watching BioKey (Cayman), Inc.? See every signal: funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planBioKey (Cayman), Inc.
AI Executive Summary
AI-powered analysis of 10-Q filing content
BioKey (Cayman), Inc. remains a pre-revenue shell-like CRO/CDMO entity with zero revenue in both the current and prior-year periods, a widening net loss (up ~60% YoY for the six-month period), and a growing stockholders' deficit now at $(5.55) million. The company is almost entirely dependent on related-party funding, with $4.63 million due to related parties and $667,613 in accrued related-party interest, raising significant going concern and liquidity concerns. Management has also disclosed that disclosure controls are not effective, reflecting weak internal control infrastructure for a newly public company.
Red Flags Detected (9)
Zero revenue reported in both Q2 2026 and Q2 2025, and for both six-month periods, despite being described as an operating pharmaceutical CRO/CDMO platform
Cash balance of only $4,618 as of June 30, 2026 — critically low operating liquidity
Stockholders' deficit widened to $(5,550,019) from $(5,073,876), a ~9.4% deterioration in six months
6 more red flags detected
Key Takeaways
Company continues to generate no revenue despite claiming to be an integrated pharmaceutical CRO/CDMO platform via subsidiary BK California
Balance sheet shows a company technically insolvent on a stockholders' equity basis, with total liabilities nearly 4.2x total assets
3 more takeaways
Filing Overview
What This Means
High Risk Filing: This company is showing signs of financial stress or significant operational challenges.
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.